Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: Results of the Chicago Pilot II study

Journal of Clinical Oncology

Volumn 20, Issue 9, 2002, Pages 2284-2292

  Kletzel, Morris ^a   Katzenstein, Howard M ^a   Haut, Paul R ^a   Yu, Alice L ^a   Morgan, Elaine ^a   Reynolds, Marleta ^a   Geissler, Grant ^a   Marymount, Maryanne H ^a   Liu, Dachao ^a   Kalapurakal, John A ^a   Shore, Richard M ^a   Bardo, Diana M E ^a   Schmoldt, Jennifer ^a   Rademaker, Alfred W ^a   Cohn, Susan L ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CHIMERIC ANTIBODY; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; IFOSFAMIDE; ISOTRETINOIN; VINCRISTINE;

ADOLESCENT; ARTICLE; ATAXIA; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; ESOPHAGITIS; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MALE; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; MUSCLE WEAKNESS; NEUROBLASTOMA; NEUTROPENIA; PANCYTOPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL RATE;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; NEUROBLASTOMA; PILOT PROJECTS; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 0036569839     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.06.060     Document Type: Article

References (32)

1. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment
2. Improved survival at 2 and 5 years in the LMCE1 unselected group of 72 children with stage IV neuroblastoma older than 1 year of age at diagnosis: Is cure possible in a small subgroup?
3. LMCE3 treatment strategy: Results in 99 consecutively diagnosed stage 4 neuroblastomas in children older than 1 year at diagnosis
4. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid
5. Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma
6. Myeloablative combination chemotherapy without total body irradiation for neuroblastoma
7. Patterns of relapse after autologous purged bone marrow transplantation for neuroblastoma: A Childrens Cancer Group pilot study
8. Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: A report of two concurrent Children's Cancer Group studies
9. Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: A report from the European Bone Marrow Transplantation Solid Tumor Registry
10. Treatment of poor-risk neuroblastoma patients with high-dose chemotherapy and autologous peripheral stem cell rescue
11. Double megatherapy and autologous bone marrow transplantation for advanced neuroblastoma: The LMCE2 study
12. Efficacy of autologous peripheral blood stem cell (PBSC) harvest and engraftment after ablative chemotherapy in pediatric patients
13. Collection and use of circulating hematopoietic progenitor cells
14. Current status of peripheral blood progenitor cell transplantation
15. Tandem high-dose therapy in rapid sequence for children with high-risk neuroblastoma
16. Advances in the diagnosis and treatment of neuroblastoma
17. Histopathologic prognostic factors in neuroblastic tumors: Definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas
18. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas
19. Detection of N-myc gene amplification by fluorescence in situ hybridization: Diagnostic utility for neuroblastoma
20. International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma
21. Two-day collection and pooling of peripheral blood stem cells with semiautomated density gradient cell separation
22. Analysis of parameters affecting engraftment in children undergoing autologous peripheral blood stem cell transplants
23. Collection and transplantation of peripheral blood stem cells in very small children weighing 20 kg or less
24. Autologous peripheral blood cell transplantation in the treatment of advanced neuroblastoma
25. Clinical collection and use of peripheral blood stem cells in pediatric patients
26. Sequential detection of tumor cells in the peripheral blood and bone marrow of patients with stage IV neuroblastoma by the reverse transcription-polymerase chain reaction for tyrosine hydroxylase mRNA
27. Circulating neuroblastoma cells detected by reverse transcriptase polymerase chain reaction for tyrosine hydroxylase mRNA are an independent poor prognostic indicator in stage 4 neuroblastoma in children over 1 year
28. Expression of GD2 ganglioside by untreated primary human neuroblastomas
29. Immunotherapy of neuroblastoma
30. High-level expression of chimeric antibodies using adapted cDNA variable region cassettes
31. Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age